Important Press Release and Letter from Ipsen Announcing They Will Reinitiate Dosing in the MOVE Trial

Dosing to begin again in patients 14 years of age and older currently enrolled in the trial

The IFOPA is sharing this important news release and community letter. If you have questions, you should contact your Principal Investigator.

Read the press release 

Read a letter from Ipsen

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter